- Home
- DMAC vs MHI Comparison
DMAC vs MHI Comparison
Compare DMAC & MHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- MHI
- Stock Information
- Founded
- DMAC 2000
- MHI 2003
- Country
- DMAC United States
- MHI United States
- Employees
- DMAC N/A
- MHI N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- MHI Investment Managers
- Sector
- DMAC Health Care
- MHI Finance
- Exchange
- DMAC Nasdaq
- MHI Nasdaq
- Market Cap
- DMAC 260.0M
- MHI 208.1M
- IPO Year
- DMAC N/A
- MHI N/A
- Fundamental
- Price
- DMAC $4.45
- MHI $8.95
- Analyst Decision
- DMAC Strong Buy
- MHI
- Analyst Count
- DMAC 4
- MHI 0
- Target Price
- DMAC $10.75
- MHI N/A
- AVG Volume (30 Days)
- DMAC 393.5K
- MHI 98.8K
- Earning Date
- DMAC 08-06-2025
- MHI 01-01-0001
- Dividend Yield
- DMAC N/A
- MHI 4.09%
- EPS Growth
- DMAC N/A
- MHI N/A
- EPS
- DMAC N/A
- MHI 0.04
- Revenue
- DMAC N/A
- MHI N/A
- Revenue This Year
- DMAC N/A
- MHI N/A
- Revenue Next Year
- DMAC N/A
- MHI N/A
- P/E Ratio
- DMAC N/A
- MHI $219.25
- Revenue Growth
- DMAC N/A
- MHI N/A
- 52 Week Low
- DMAC $3.19
- MHI $6.93
- 52 Week High
- DMAC $6.82
- MHI $9.05
- Technical
- Relative Strength Index (RSI)
- DMAC 53.15
- MHI 40.01
- Support Level
- DMAC $4.81
- MHI $8.84
- Resistance Level
- DMAC $5.60
- MHI $8.93
- Average True Range (ATR)
- DMAC 0.49
- MHI 0.05
- MACD
- DMAC 0.05
- MHI -0.01
- Stochastic Oscillator
- DMAC 43.21
- MHI 34.37
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About MHI Pioneer Municipal High Income Fund Inc.
Pioneer Municipal High Income Trust is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income exempt from regular federal income tax and capital appreciation. The trust invests in various sectors such as health, education, tobacco, facilities, transportation, utilities, airport, water, and other sectors.